Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08GIM
|
|||
| Former ID |
DIB013107
|
|||
| Drug Name |
Elisidepsin
|
|||
| Synonyms |
Irvalec; Elisidepsin trifluoroacetate; PM-02734; Erbb3 tyrosine kinase receptor inhibitor (cancer), PharmaMar; Kahalalide therapy (solid tumor), PharmaMar
Click to Show/Hide
|
|||
| Indication | Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Phase 2 | [1] | |
| Company |
PharmaMar SA
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C75H124N14O16
|
|||
| Canonical SMILES |
CCC(C)CCC(=O)NC(C(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)N1CCCC1C(=O)NC(CCCN)C(=O)NC(C(C)CC)C(=O)NC2C(OC(=O)C(NC(=O)C(=CC)NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)C(C)CC)C(C)C)CC3=CC=CC=C3)C(C)C)C
|
|||
| InChI |
1S/C75H124N14O16/c1-20-43(15)33-34-53(91)80-54(38(5)6)68(97)87-61(46(18)90)72(101)82-56(40(9)10)69(98)83-57(41(11)12)74(103)89-36-28-32-52(89)66(95)78-50(31-27-35-76)64(93)85-59(44(16)21-2)71(100)88-62-47(19)105-75(104)58(42(13)14)84-63(92)49(23-4)77-65(94)51(37-48-29-25-24-26-30-48)79-67(96)55(39(7)8)81-70(99)60(45(17)22-3)86-73(62)102/h23-26,29-30,38-47,50-52,54-62,90H,20-22,27-28,31-37,76H2,1-19H3,(H,77,94)(H,78,95)(H,79,96)(H,80,91)(H,81,99)(H,82,101)(H,83,98)(H,84,92)(H,85,93)(H,86,102)(H,87,97)(H,88,100)/b49-23-/t43-,44-,45-,46+,47+,50-,51-,52+,54+,55+,56-,57+,58-,59+,60+,61-,62+/m0/s1
|
|||
| InChIKey |
ZNVCPJPCKSJWDH-UCTDCHLSSA-N
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:83152
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Erbb3 tyrosine kinase receptor (Erbb-3) | Target Info | Inhibitor | [2] |
| KEGG Pathway | ErbB signaling pathway | |||
| Calcium signaling pathway | ||||
| Endocytosis | ||||
| Proteoglycans in cancer | ||||
| MicroRNAs in cancer | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Panther Pathway | Cadherin signaling pathway | |||
| EGF receptor signaling pathway | ||||
| Pathway Interaction Database | ErbB2/ErbB3 signaling events | |||
| ErbB receptor signaling network | ||||
| a6b1 and a6b4 Integrin signaling | ||||
| WikiPathways | ErbB Signaling Pathway | |||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
| Signaling Pathways in Glioblastoma | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| Heart Development | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug;33(4):901-10. | |||
| REF 2 | Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer. 2009 Jul;45(10):1855-64. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.